Genomic Vision Announces Promising Preliminary Results for Its Clinical Study in Cervical Cancer Detection in the Czech Repub...
May 10 2017 - 1:00AM
Business Wire
Interim results of the HPV clinical trial
validate the integration of the oncogenic high-risk human
papillomavirus (HPV-HR) as an indicator of the severity of
precancerous lesions.
Regulatory News:
Genomic Vision (Paris:GV) (Euronext: FR0011799907 – GV),
a company specialized in the development of diagnostic tests for
the early detection of cancers and genetic diseases, today
announces promising interim results of its clinical trial organized
in the Czech Republic for the cervical cancer detection.
Launched in July 2016, the EXPL-HPV-002 study led in two major
clinical centers, the Brno Centre for Outpatient Gynaecology and
Primary Care (Dr. Vladimír Dvořák, principal investigator of the
study) and the Brno University Hospital (Prof. Pavel Ventruba) has
for primary end-point to evaluate the integration of HPV virus
(Human Papillomavirus) as a diagnostic biomarker of the high-risk
precancerous lesions, requiring an appropriate care.
To date, while 300 female patients aged between 25 and 65 years
old have already been recruited, the interim analysis with the
first 126 patients allows to demonstrate that the integration of 14
HR-HPV detected by molecular combing represents a relevant
indicator of the precancerous lesions’ progression and their degree
of severity.
Dr Vladimír Dvořák, Head Physician at the Brno Centre for
Outpatient Gynaecology and Primary Care, declared: “These first
results demonstrate the suitability of the molecular combing in
order to improve the early diagnosis of cervical cancer. The
clinical demonstration of the HR-HPV integration as progressive key
factor towards the disease highlights a very strong prognostic
value. We look forward to confirming these promising data on the
whole cohort of patients."
Aaron Bensimon, CEO and co-founder of Genomic Vision,
concluded: “The HPV infection, at the origin of the
cervical cancer in certain cases, is one of the major threats for
women’s health. We know that adapted care through an early
diagnosis of the disease significantly increase the life
expectancy. The interim collected data of the EXPL-HPV-002 study
are extremely encouraging and need to be replicated in the future
on a larger number of patients. The accurate analysis of the final
results expected by the end of the year should allow to position
our technology as a new standard for premature detection of this
cancer, 3rd most wide-spread within female population at the origin
of 275.00 deaths a year.”
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 60 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907). For further information,
please visitwww.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section in its Document de
Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509006833/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorMilestonesPress
RelationsBruno Arabian, +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel Huynh, +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2024 to May 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From May 2023 to May 2024